pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors.

Licensing 72

Licensing Licensing Trials Clinical Trials 72

Drug Discovery World

FEBRUARY 23, 2023

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

Drugs 52

Drugs Licensing Licensing Protein 52

pharmaphorum

JULY 14, 2022

The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.

Drugs 92

Drugs Sales Pharma Companies Cardiology 92

Pharmaceutical Technology

APRIL 17, 2023

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. The US Food and Drug Administration (FDA) granted Eli Lilly’s Lartruvo (olaratumab) accelerated approval in 2016 for soft tissue sarcoma (STS). After this, Telix licenced the drug for $5m.

Development 130

Development Antibody Pharma Companies Licensing 130

pharmaphorum

MAY 20, 2022

In one of the first moves by a member of ATOM, Novartis has agreed to license rights to its tyrosine kinase inhibitor drug nilotinib – sold as Tasigna as a leukaemia treatment – to the UN-backed Medicines Patent Pool (MPP). The post Coalition aims to improve cancer drug access in poorer nations appeared first on.

Drugs 111

Drugs Medicine Licensing Licensing 111

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

pharmaphorum

JANUARY 7, 2022

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery. The post Another big AI deal as Sanofi taps Exscientia for 15 new drugs appeared first on. Shortly after Amgen unveiled its $1.9

Drugs 106

Drugs Pharma Companies Medicine Licensing 106

pharmaphorum

JUNE 14, 2021

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Drugs 99

Drugs Pharma Companies Licensing Licensing 99

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 96

Drugs Antibody Pharma Companies Development 96

XTalks

AUGUST 21, 2023

The US Food and Drug Administration (FDA) has approved Ipsen’s groundbreaking Sohonos (palovarotene) capsules for the treatment of fibrodysplasia ossificans progressive (FOP), an ultra-rare bone disease. Sohonos, the first and only approved drug, offers hope to those battling the disease.

Drugs 98

Drugs FDA Approval Genetics Clinical Trials 98

pharmaphorum

FEBRUARY 12, 2021

Along with the $350 million upfront fee Sandoz is also pledging $150 million tied to sales performance in the deal, which excludes some rights to the drug in some markets including the US, China, Germany and Australia. The post Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs appeared first on.

Drugs 111

Drugs Sales Pharma Companies Marketing 111

Fossil Remedies

SEPTEMBER 23, 2022

PCD Pharma Franchise is a popular business model. It is a business arrangement in which a pharma company offers the rights of marketing and distribution to its franchise partner. The pharma company thus expands its business and reaches new regions. Check the market reputation and image of the company.

Pharma Companies 52

Pharma Companies Production Licensing Licensing 52

pharmaphorum

MAY 13, 2022

Bristol-Myers Squibb’s flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy Opdivo. The post BMS doubles down on BridgeBio alliance on SHP2 drugs appeared first on.

Drugs 59

Drugs Pharma Companies Licensing Licensing 59

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

FEBRUARY 5, 2024

However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system. The new data was released by pharma company Clinigen to mark the start of Rare Disease Month.

Medicine 52

Medicine Pharma Companies Licensing Licensing 52

World of DTC Marketing

APRIL 12, 2021

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. We can’t continue to develop drugs the same way as we have done before.

Generic Drugs 187

Generic Drugs Manufacturing Production Drugs 187

pharmaphorum

JUNE 2, 2021

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic dermatitis or eczema. . Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 119

Licensing Licensing Marketing Sales 119

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

DECEMBER 6, 2022

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics.

Licensing 52

Licensing Licensing Antibody Clinical Trials 52

pharmaphorum

FEBRUARY 11, 2022

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. billion takeover of Clementia Pharma in 2019. billion of its revenues last year. billion of its revenues last year.

Sales 96

Sales Pharma Companies Branding Cosmetics 96

Pharmaceutical Technology

AUGUST 1, 2022

The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines. As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. However, to invest in drug development for this condition, a number of methodological issues will need to be addressed.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 63

Antibody Licensing Licensing Sales 63

pharmaphorum

SEPTEMBER 20, 2022

Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has converted the relationship into a lucrative, wide-ranging contract. ” He goes on: “That’s exactly what our computational disease models are designed to do. .”

Pharma Companies 52

Pharma Companies Trials Engineer Development 52

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is already in the late stages of development and expected to be approved in Europe later this year.

Licensing 52

Licensing Licensing Pharma Companies Branding 52

pharmaphorum

APRIL 22, 2021

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions. The company has an “asset focused” R&D philosophy , where development is centred on the needs of each individual biotech.

Licensing 54

Licensing Licensing Pharma Companies Drugs 54

Camargo

SEPTEMBER 23, 2020

Panel Summary from the World Orphan Drug Congress 2020. Last month, executives from leading international biopharma companies came together at the World Orphan Drug Congress 2020 to discuss how they are evaluating new opportunities in the rare disease space. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 Lilly is thought to be the first pharma company to sign up to use the new camptothecin payload platform. million payment to the biotech.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

JANUARY 20, 2022

The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces. Lotus CEO, Petar Vazharov, said the partnership would ensure that the novel spray drug is accessible to patients in South East Asia.

Allergies 72

Allergies Marketing Manufacturing Production 72

pharmaphorum

JANUARY 24, 2023

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the field of inflammatory bowel disease (IBD). Image source: Kindel Media on Pexels.

Medicine 52

Medicine Drugs Pharma Companies Clinical Trials 52

Fossil Remedies

AUGUST 21, 2019

It is an agreement between a franchiser which is typically a pharma manufacturing (or marketing) company where a franchisee is an individual entrepreneur or a small company that buys the license. Why is it a great idea to launch a pharma franchise? Drug license copy (wholesaler/retailer).

Pharma Companies 40

Pharma Companies Production Licensing Licensing 40

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. Interest in the target has also prompted a flurry of licensing deals.

Antibody 92

Antibody Protein Gene Therapy Pharma Companies 92

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. In that respect it follows a similar model to Merck’s takeover of AmpTec, another CDMO that uses a PCR platform to make mRNA drugs, for an undisclosed sum last year.

Vaccination 98

Vaccination Vaccine Manufacturing Life Science 98

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences. About the author.

Medicine 119

Medicine Pharma Companies Vaccination Vaccine 119

pharmaphorum

NOVEMBER 16, 2022

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK retain the number one position, newly joined by Johnson & Johnson in second and AstraZeneca in third.

Medicine 105

Medicine Production Pharma Companies Licensing 105